An exploratory clinical study of fluzoparib combined with bevacizumab in the maintenance treatment of RAS mutant colorectal cancer after first-line chemotherapy

ABSTRACT: Interventions: Experimental group:fluzoparib combined with bevacizumab Primary outcome(s): Progression-free survival Study Design: Single arm

DISEASE(S): Ras Mutant Colorectal Cancer

PROVIDER: 2726186 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR